Evaluation of Permeability and P-glycoprotein Interactions: Industry Outlook

  • Praveen V. Balimane
  • Saeho Chong

New drug discovery and development is becoming an increasingly risky and costly endeavor.A recent report has tagged the final price of bringing a drug to the market at greater than a billion US dollars with an estimated research time running into multiple years (2004). Despite the considerable investment in terms of finance and resources, the number of drug approvals per year have held steady for the last few years. The advent of combinatorial chemistry, automation, and high-throughput screening (HTS) has afforded the opportunity to test thousands of compounds, but the success rate of progressing from initial clinical testing to final approval has remained disappointingly low. Greater than 90% of the compounds entering Phase-I clinical testing fail to reach the patients and as high as 50% entering Phase-III do not make the cut (Kola and Landis, 2004).


MDCK Cell Ussing Chamber Permeability Assay Early Drug Discovery Polar Molecular Surface Area 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adachi Y, Suzuki H and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-gp. Pharmaceutical Research 18:1660-1668.CrossRefPubMedGoogle Scholar
  2. Anderle P, Huang Y and Sadee W (2004) Intestinal membrane transport of drugs and nutri-ents: genomic membrane transporters using expression microarray. European Journal of Pharmaceutical Sciences 21:17-24.CrossRefPubMedGoogle Scholar
  3. Ano R, Kimura Y, Shima M, Matsuno R, Ueno T and Akamatsu M (2004) Relationship between structure and high-throughput screening permeability of papetide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorganic & Medicinal Chemistry 12:257-264.CrossRefGoogle Scholar
  4. Arturrson P (1991) Cell cultures as models for drug absorption across the intestinal mucosa. Critical Reviews in Therapeutic Drug Carrier Systems 8:305-330.Google Scholar
  5. Artursson P and Borchardt R (1997) Intestinal drug absorption and metabolism in cell cul-tures: Caco-2 and beyond. Pharmaceutical Research 14:1655-1658.CrossRefPubMedGoogle Scholar
  6. Artursson P and Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelia (Caco-2) cells. Biochemical and Biophysical Research Communications 175:880-890.CrossRefPubMedGoogle Scholar
  7. Artursson P, Palm K and Luthman K (1996) Caco-2 monolayers in experimental and theo-retical predictions of drug transport. Advanced Drug Delivery Reviews 22:67-84.CrossRefGoogle Scholar
  8. Aungst B, Nguyen N, Bulgarelli J and Oates-Lenz K (2000) The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharmaceutical Research 17:1175-1180.CrossRefPubMedGoogle Scholar
  9. Avdeef A (2001) Physicochemical profiling (solubility, permeability and charge state). Cur-rent Topics in Medicinal Chemistry 1:277-351.CrossRefGoogle Scholar
  10. Balimane PV and Chong S (2005a) Cell culture-based models for intestinal permeability: a critique. Drug Discovery Today 10:335-343.CrossRefPubMedGoogle Scholar
  11. Balimane PV and Chong S (2005b) A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. International Journal of Pharmaceutics 301:80-88.CrossRefPubMedGoogle Scholar
  12. Balimane PV, Chong S and Morrison RA (2000) Current methodologies used for evaluation of intestinal permeability and absorption. Journal of Pharmacological and Toxicological Methods 44:301-312.CrossRefPubMedGoogle Scholar
  13. Balimane PV, Han YH and Chong S (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPSJ 8:E1-13.CrossRefPubMedGoogle Scholar
  14. Behrens I, Kamm W, Dantzig A and Kissel T (2004) Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. Journal of Pharmaceutical Sciences 93:1743-1754.CrossRefPubMedGoogle Scholar
  15. Beigi F, Yang Q and Lundahl P (1995) Immobilized-liposome chromatographic analysis of drug partitioning into lipid bilayers. Journal of Chromatography A. 704:215-321.CrossRefGoogle Scholar
  16. Braun A, Hammerle S, Suda K, Rothen-Rutishauser B, Gunthert M and WunderliAllenspach H (2000) Cell cultures as tools in biopharmacy. European Journal of Pharmaceutical Sciences 11:S51-S60.CrossRefPubMedGoogle Scholar
  17. Carr K and Toner P (1984) Morphology of the Intestinal Mucosa, in Pharmacology of the Intestine (Csaky T ed) pp 1-50, Springer, Berlin Heidelberg New York.Google Scholar
  18. Chen Z, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M and Akiyama S (1999) Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Molecular Pharmacology 56:1219-1228.PubMedGoogle Scholar
  19. Cho M, Thomson D, Cramer C, Vidmar T and Scieszka J (1989) The MDCK epithelial cell monolayer as a model cellular transport barrier. Pharmaceutical Research 6:71-77.CrossRefPubMedGoogle Scholar
  20. Chong S, Dando S, Soucek K and Morrison R (1996) In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharmaceutical Research 13:120-123.CrossRefPubMedGoogle Scholar
  21. Clark D (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. Journal of Pharmaceutical Sciences 88:807-814.CrossRefPubMedGoogle Scholar
  22. Dantzig A, Shepard R, Law K, Tabas L, Pratt S, Gillespie J, Binkley S, Kuhfeld M, Starling J and Wrighton S (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-gp and effect on CYP-450 activities. Journal of Pharmacology and Experimental Therapeutics 290:854-562.PubMedGoogle Scholar
  23. Daugherty A and Mrsny R (1999) Regulation of the intestinal epithelial paracellular barrier. Pharmaceutical Sciences and Technology Today 2:281-287.CrossRefGoogle Scholar
  24. Di L, Kerns EH, Fan K, McConnell OJ and Carter GT (2003) High throughput artificial membrane permeability assay for blood-brain barrier. European Journal of Medicinal Chemistry 38:223-232.CrossRefPubMedGoogle Scholar
  25. Dimitrijevic D, Shaw A and Florence A (2000) Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells. Journal of Pharmacy and Pharmacology 52:157-162.CrossRefPubMedGoogle Scholar
  26. Doluisio J, Billups N, Dittert L, Sugita E and Swintosky J (1969) Journal of Pharmaceutical Sciences 58:1196-1200.CrossRefPubMedGoogle Scholar
  27. Dressman J (1986) Comparison of canine and human gastrointestinal physiology. Pharma-ceutical Research 3:123-131.CrossRefGoogle Scholar
  28. Dressman J, Amidon G and Fleisher D (1985) Absorption potential: estimating the fraction absorbed for orally administered compounds. Journal of Pharmaceutical Sciences 74:588-589.CrossRefPubMedGoogle Scholar
  29. Dressman J, Berardi R, Dermentzoglou L, Russell T, Schmaltz S, Barnett J and Jarvenpaa K (1990) Upper gastrointestinal (GI) pH in young, healthy men and women. Pharmaceutical Research 7:756-761.CrossRefPubMedGoogle Scholar
  30. FDA (2004) Challenges and opportunity on the critical path to new medical products. FDA Report.Google Scholar
  31. Grass G and Sweetana S (1989) A correlation for permeabilities of passively transported compounds in monkey and rabbit jejunum. Pharmaceutical Research 6:857-862.CrossRefPubMedGoogle Scholar
  32. Gres M, Julian B, Bourrie M, Meunier V, Roques C, Berger M, Boule, Berger Y and Fabre G (1998) Correlation between oral drug absorption in humans, apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharmaceutical Research 15:726-733.CrossRefPubMedGoogle Scholar
  33. Hidalgo I (2001) Assessing the absorption of new pharmaceuticals. Current Topics in Medi-cinal Chemistry 1:385-401.CrossRefGoogle Scholar
  34. Hillgren K, Kato A and Borchardt R (1995) In vitro systems for studying intestinal drug absorption. Medical Research Reviews 15:83-109.CrossRefGoogle Scholar
  35. Ho N, Park J, Morozowich W and Higuchi W (1977) Physical model approach to the design of drugs with improved intestinal absorption, in Design of biopharmaceutical properties through prodrugs and analogues. (Roche E ed) pp 136-277, APhA/APS, Washington, DC.Google Scholar
  36. Horie K, Tang F and Borchardt R (2003) Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance efflux transporter. Pharmaceutical Research 20:161-168.CrossRefPubMedGoogle Scholar
  37. Houston J, Upshall D and Bridges J (1974) A Reevaluation of the importance of partition coefficients in the gastrointestinal absorption of nutrients. The Journal of Pharmacology and Experimental Therapeutics 189:244-254.PubMedGoogle Scholar
  38. Irvine J, Takahashi L, Lockhart K, Cheong J, Tolan J, Selick H and Grove J (1999) MDCK cells: a tool for membrane permeability screening. Journal of Pharmaceutical Sciences 88:28-33.CrossRefPubMedGoogle Scholar
  39. Kansy M, Senner F and Gubernator K (1998) Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. Journal of Medicinal Chemistry 41:1007-1010.CrossRefPubMedGoogle Scholar
  40. Kararli T (1995) Comparison of the gastrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals. Biopharmaceutics & Drug Disposition 16:351-380.CrossRefGoogle Scholar
  41. Kerns E, Di L, Petusky S, Farris M, Ley R and Jupp P (2004) Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. Journal of Pharmaceutical Sciences 93:1440-1453.CrossRefPubMedGoogle Scholar
  42. Kim R, Wendel C, Leake B, Cvetkovic M, Fromm M, Dempsey P, Roden M, Belas F, Chaudhary A, Roden D, Wood A and Wilkinson G (1999) Interrelationship between sub-strates and inhibitors of human CYP3A and P-gp. Pharmaceutical Research 16:408-414.CrossRefPubMedGoogle Scholar
  43. Kola I and Landis J (2004) Can pharmaceutical industry reduce attrition rates? Nature Reviews: Drug Discovery 3:711-715.CrossRefPubMedGoogle Scholar
  44. Komiya I, Park J, Yamani A, Ho N and Higuchi W (1980) International Journal of Phar-maceutics 4:249-262.CrossRefGoogle Scholar
  45. Krause E, Dathe M, Wieprecht T and Bienert M (1999) Noncovalent immobilized artifi-cial membrane chromatography, an improved method for describing peptide-lipid bilayer interactions. Journal of Chromatography 849:125-133.CrossRefPubMedGoogle Scholar
  46. Krishna R and Mayer LD (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. European Journal of Pharmaceutical Sciences 11 (4):265-83.CrossRefPubMedGoogle Scholar
  47. Krishna G, Chen K, Lin C and Nomeir A (2001) Permeability of lipophilic compounds in drug discovery using in vitro human absorption model, Caco-2. International Journal of Pharmaceutics 222:77-89.CrossRefPubMedGoogle Scholar
  48. Lee K, Brower K and Thakker D (2002) Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. Journal of Pharmacological and Toxicological Methods 303:574-580.Google Scholar
  49. Lennernas H (1998) Human intestinal permeability. Journal of Pharmaceutical Sciences 87:403-410.CrossRefPubMedGoogle Scholar
  50. Lennernas H, Nylander S and Ungell A (1997) Jejunal permeability: a comparison between the Ussing chamber technique and the single pass perfusion in humans. Pharmaceutical Research 14:667-671.CrossRefPubMedGoogle Scholar
  51. Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals 23:1008-1021.Google Scholar
  52. Lin J (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Advanced Drug Delivery Reviews 55:53-81.CrossRefPubMedGoogle Scholar
  53. Lin J and Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics. Clinical Pharmacokinetics 42:59-98.CrossRefPubMedGoogle Scholar
  54. Lipinski T, Lombardo F, Dominy B and Feeney P (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 23:3-25.CrossRefGoogle Scholar
  55. Maliepaard M, van Gastelen M, Tohgo A, Hauseer F, van Waardengurg R, de Jong L, Pluim D, Beijnen J and Schellens J (2001) Circumvention of BCRP-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clinical Caner Research 7:935-941.Google Scholar
  56. Murer H and Kinne R (1980) The use of isolated vesicles to study epithelial transport processes. The Journal of Membrane Biology 55:81-95.CrossRefPubMedGoogle Scholar
  57. Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P and Artursson P (1998) Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. Journal of Medical Chemistry 41:5382-5392.CrossRefGoogle Scholar
  58. Perloff M, Stromer E, von Moltke L and Greenblatt D (2003) Rapid assessment of P-gp inhibition and induction in vitro. Pharmaceutical Research 20:1177-1183.CrossRefPubMedGoogle Scholar
  59. Pidgeon C (1990a) Immobilized artificial membranes, in US patent p 498.Google Scholar
  60. Pidgeon C (1990b) Solid phase membrane mimetics: immobilized artificial membranes. Enzyme and Microbial Technology 12:149-150.CrossRefPubMedGoogle Scholar
  61. Polli J, Jerrett J, Studenberg J, Humphreys J, Dennis S, Brower K and Wooley J (1999) Role of P-gp on CNS disposition of amprenavir, an HIV protease inhibitor. Pharmaceutical Research 16:1206-1212.CrossRefPubMedGoogle Scholar
  62. Polli J, Wring S, Humphreys J, Huang L, Morgan J, Webster L and Serabjit-Singh C (2001) Rational use of in vitro P-gp assays in drug discovery. The Journal of Pharmacology and Experimental Therapeutics 299:620-628.PubMedGoogle Scholar
  63. Quastel J (1961) Methods of study of Intestinal absorption and Metabolism, in Methods in Medical Research (Quastel J ed) pp 255-259, Year Book Medical Publishers, Chicago.Google Scholar
  64. Rege B, Yu L, Hussain A and Polli J (2001) Effect of common excipients on caco-2 trans-port of low-permeability drugs. Journal of Pharmaceutical Sciences 90:1776-1786.CrossRefPubMedGoogle Scholar
  65. Rege B, Kao J and Polli J (2002) Effect of non-ionic surfactants on membrane transport in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences 16:237-246.CrossRefPubMedGoogle Scholar
  66. Rubas W, Jezyk N and Grass GM (1993) Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharmaceutical Research 10:113-118.CrossRefPubMedGoogle Scholar
  67. Rubas W, Cromwell M, Shahrokh Z, Villagran J, Nguyen T, Welton M, Nguyen T and Mrsny R (1996) Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. Journal of Pharmaceutical Sciences 85:165-169.CrossRefPubMedGoogle Scholar
  68. Ruell JA, Tsinman KL and Avdeef A (2003) PAMPA - a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pK a(flux) - optimized design (pOD-PAMPA). European Journal of Pharmaceutical Sciences 20:393-402.CrossRefPubMedGoogle Scholar
  69. Russell T, Berardi R, Barnett J, Dermentzoglou L, Jarvenpaa K, Schmaltz S and Dressman J (1993) Upper gastrointestinal pH in 79 healthy, elderly, north American men and women. Pharmaceutical Research 10:187-196.CrossRefPubMedGoogle Scholar
  70. Saha P and Kou J (2002) Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. European Journal of Pharmaceutics and Biopharmaceutics 54:319-324.CrossRefPubMedGoogle Scholar
  71. Schanker L, Tocco D, Brodie B and Hogben C (1958) Absorption of drugs from the rat small intestine. The Journal of Pharmacology and Experimental Therapeutics. 123:81-88.PubMedGoogle Scholar
  72. Schurgers N and DeBlaey C (1984) International Journal of Pharmaceutics 19:283-295.CrossRefGoogle Scholar
  73. Simpson K and Jarvis B (2000) Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59:301-321.CrossRefPubMedGoogle Scholar
  74. Sinko PJ, Hu P, Waclawski AP and Patel NR (1995) Oral absorption of anti-AIDS nucleo-side analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations. Journal of Pharmaceutical Sciences 84:959-965.CrossRefPubMedGoogle Scholar
  75. Stenberg P, Luthman K, Ellens H, Lee CP, Smith PL, Lago A, Elliott JD and Artursson P (1999) Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharmaceutical Research 16:1520-1526.CrossRefPubMedGoogle Scholar
  76. Stewart BH and Chan OH (1998) Use of immobilized artificial membrane chromatography for drug transport applications. Journal of Pharmaceutical Sciences 87:1471-1478.CrossRefPubMedGoogle Scholar
  77. Sun D, Lennernas H, Welage L, Barnett J, Landowski C, Foster D, Fleisher D, Lee K and Amidon G (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequence tags and correlation with permeability of 26 drugs. Pharmaceutical Research 19:1400-1416.CrossRefPubMedGoogle Scholar
  78. Tavelin S, Taipalensuu J, Hallbook F, Vellonen K, Moore V and Artursson P (2003) An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes. Pharmaceutical Research 20:373-381.CrossRefPubMedGoogle Scholar
  79. Uhing M and Kimura R (1995) The effect of surgical bowel manipulation and anesthesia on intestinal glucose absorption in rats. The Journal of Clinical Investigation 95:2790-2798.CrossRefPubMedGoogle Scholar
  80. Ungell A-L (2004) Caco-2 replace or refine? Drug Discovery Today 1:423-430.CrossRefGoogle Scholar
  81. Ungell A, Nylander S, Bergstrand S, Sjoberg A and Lennernas H (1998) Membrane transport of drugs in different regions of the intestinal tract of the rat. Journal of Pharmaceutical Sciences 87:360-366.CrossRefPubMedGoogle Scholar
  82. Ussing H and Zerahn K (1951) Active transport of sodium as a source of electric current in the short-circuited isolated frog skin. Acta Physiologica Scandinavica 23:110-127.CrossRefPubMedGoogle Scholar
  83. Van Rees H, De Wolff F and Noach E (1974) European Journal of Pharmacology 28:310-315.CrossRefPubMedGoogle Scholar
  84. Volk E and Schneider E (2003) Wild type BCRP is a methotrexate ployglutamate transporter. Cancer Research 63:5538-5543.PubMedGoogle Scholar
  85. Walter E and Kissel T (1995) Heterogeneity in the human intestinal cell line Caco-2 leads to differences in transepithelial transport. European Journal of Pharmaceutical Sciences 3:215-230.CrossRefGoogle Scholar
  86. Watanabe T, Miyauchi S, Sawada Y, Iga T, Hanano M, Inaba M and Sugiyama Y (1992) Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: possible roles of P-gp in biliary excretion of vincristine. Journal of Hepatology 16:77-88.CrossRefPubMedGoogle Scholar
  87. Wessel M, Jurs P, Tolan J and Muskal S (1998) Prediction of human intestinal absorption of drug compounds. Journal of Chemical Information and Computer Sciences 38:726-735.PubMedGoogle Scholar
  88. Wilson T and Wiseman G (1954) The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. The Journal of Physiology 123:116-125.PubMedGoogle Scholar
  89. Woehlecke H, Pohl A, Alder-Berens N, Lage H and Herrmann A (2003) Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochemical Journal 376:489-495.CrossRefPubMedGoogle Scholar
  90. Yamazaki M, Neway W, Ohe T, Chen I, Rowe J, Hochman J, Chiba M and Lin J (2001) In vitro substrate identification studies for P-gp mediated transport: Species difference and predictability of in vivo results. The Journal of Pharmacology and Experimental Therapeutics 296:723-735.PubMedGoogle Scholar
  91. Yang C, Cai S, Liu H and Pidgeon C (1996) Immobilized artificial membranes - screens for drug membrane interactions. Advanced Drug Delivery Reviews 23:229-256.CrossRefGoogle Scholar
  92. Zhang S, Yang X and Morris M (2004) Flavonoids are inhibitors of BCRP-mediated transport. Molecular Pharmacology 65:1208-1216.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Praveen V. Balimane
    • 1
  • Saeho Chong
    • 1
  1. 1.Bristol-Myers Squibb CompanyNew BrunswickUSA

Personalised recommendations